

TML: CS: 2017-18:

4th September, 2017

The General Manager
Dept. of Corporate Services
Bombay Stock Exchange Ltd.
Rotunda Building, 1st Floor,
Mumbai Samachar Marg,
Mumbai- 400 001.

The Vice President
Listing Department,
National Stock Exchange of India Ltd.
"Exchange Plaza", Bandra – Kurla
Complex,
Bandra – East,
Mumbai- 400 051.

Dear Sir/Madam,

Sub: Outcome of the Board Meeting

Meeting Commencement time : 11:45 A.M
Meeting Conclusion Time : 12:50 P.M

The Board of Directors at its meeting held today, approved the following matters:

1. Approved the Unaudited Standalone Financial Results of the Company for the Quarter ended on 30th June, 2017.
2. Allotment of 1940 Equity shares to eligible employees' pursuant exercise of ESOP options under Themis ESOS Scheme 2012.

A copy of Unaudited Standalone Financial Results of the Company for the Quarter ended on 30th June, 2017 together with Limited Review Report is enclosed for your perusal.

This may be taken as compliance under the Listing Regulations.

Kindly take the same on record and acknowledge receipt.

Thanking you,
Yours faithfully,

For **THEMIS MEDICARE LIMITED**



SANGAMESHWAR IYER
COMPANY SECRETARY



Themis Medicare Limited

Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai - 400 104 India
Tel. : 91-22-6760 7080 • **Fax** : 91-22-6760 7070 / 2874 6621

Regd. Office : Plot No. 69-A, G.I.D.C. Industrial Estate, Vapi - 396 195, Gujarat

CIN No.: L24110GJ1969PLC001590 • **Tel / Fax No.**: **Regd. Off.** : 0260 2431447 / 2430219

• **E-mail** : themis@themismedicare.com • **Website** : www.themismedicare.com

M. T. ANKLESHWARIA & CO.
CHARTERED ACCOUNTANTS
MADHU T. ANKLESHWARIA
B.COM. (HONS) F.C.A.

TEL: 2614 9392
7, GOKUL NIWAS,
47, BAJAJ ROAD,
VILE PARLE (WEST),
MUMBAI - 400 056
mtankleshwaria@yahoo.com

To
Board of Directors of
THEMIS MEDICARE LIMITED
Mumbai

RE: Limited Review of the Unaudited Standalone Financial Results for the Quarter ended on June 30, 2017

We have reviewed the accompanying statement of Unaudited Standalone Financial Results of Themis Medicare Limited (the 'Company') for the quarter ended June 30, 2017 (the 'Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.

The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of Companies (India Accounting Standards) Rules, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standard ('Ind AS') specified under Section 133 of the Companies Act,



2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We have not reviewed the Financial Results and other financial information for the corresponding quarter ended June 30, 2016, which have been presented solely based on the information compiled by the Management and has been approved by the Board of Directors of the Company.

For **M.T.ANKLESHWARIA & CO,**
CHARTERED ACCOUNTANTS
Registration No. 100501W



A handwritten signature in black ink, appearing to read "Madhu T. Ankleshwaria".

MADHU T. ANKLESHWARIA
PROPRIETOR
Membership No. 30128

Place: Mumbai
Date: 04.09.2017

THEMIS MEDICARE LTD

CIN NO : L24110GJ1969PLC001590

Regd. Off. Plot No. 69A, GIDC Indl. Estate, Vapi - 396195, Dist Valsad, Gujarat. (T) 0260-2431447 / 0260-2430219.

Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai-400 104.

Email ID : themis@themismedicare.com. Website Address : www.themismedicare.com.

Statement of Unaudited Financial Results for the quarter ended 30th June 2017.

(Amount in INR Lacs)

	Particulars	STANDALONE	
		3 months ended	Corresponding 3 months ended
		30/06/2017	30/06/2016
		(Unaudited)	(Unaudited)
1	Revenue from Operations	4,744.00	5,785.15
2	Other Income	27.43	185.83
3	Total Income (1 + 2)	4,771.43	5,970.98
4	Expenses :		
	(a) Cost of materials consumed	1,172.29	1,330.76
	(b) Purchases of stock-in-trade	666.65	430.06
	(c) Changes in inventories of finished goods,work-in-progress and stock-in-trade	(298.09)	262.76
	(d) Excise Duty	220.34	105.56
	(e) Employee benefits expense	1,065.34	1,018.39
	(f) Finance Costs	299.70	312.13
	(g) Depreciation and amortisation expense	170.64	171.76
	(h) Other expenses	1,857.10	1,837.17
	Total expenses	5,153.97	5,468.59
5	Profit / (Loss) before exceptional and extraordinary items and tax (3 - 4)	(382.54)	502.39
6	Exceptional items	-	-
7	Profit / (Loss) before extraordinary items and tax (5 - 6)	(382.54)	502.39
8	Extraordinary items	-	-
9	Profit / (Loss) before tax (7 - 8)	(382.54)	502.39
10	Tax expense :		
	(a) Current Tax	-	-
	(b) Deferred Tax	(13.55)	(13.55)
11	Profit / (Loss) for the period (9 - 10)	(368.99)	515.94
12	Other Comprehensive Income :		
	(a i) Items that will not be reclassified to Profit & Loss	0.65	0.17
	(a ii) Income Tax relating to Items that will not be reclassified to Profit & Loss	(0.06)	(0.06)
	(b) Items that will be reclassified to Profit & Loss	-	-
13	Total Comprehensive Income (11 + 12)	(368.40)	516.05
14	Paid up Equity Share Capital (Face Value of Rs.10/- per Equity Share)	904.44	901.96
15	Earnings per share :		
	(a) Basic	(4.07)	5.72
	(b) Diluted	(3.97)	5.56



THEMIS MEDICARE LTD

CIN NO : L24110GJ1969PLC001590

Regd. Off. Plot No. 69A, GIDC Indl. Estate, Vapi - 396195, Dist Valsad, Gujarat. (T) 0260-2431447 / 0260-2430219.

Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai-400 104.

Email ID : themis@themismedicare.com. Website Address : www.themismedicare.com.

NOTES :

- 1) The Company has only one segment namely pharmaceuticals, hence no separate segmentwise disclosure has been made.
- 2) During the quarter under review paid up capital of the Company increased from Rs. 903.94 lacs to Rs. 904.44 lacs in view of allotment of 4929 equity shares on exercise of ESOP by some of the eligible employees.
- 3) In terms of SEBI (ICDR) Regulations, 2009 the Board at its meeting held on 17th June, 2016 allotted 500000 Equity Shares on Preferential Basis to Non Promoters and 125000 Convertible Warrants to some of the Promoters of the Company. The proceeds received amounted to Rs. 2656.25 lacs. In terms of the Regulation 32 of the SEBI (LODR) Regulations, 2015 we state that there was no deviation of proceeds utilised for the period ended June, 2017 from the purposes mentioned in Private Placement Offer Letter.
- 4) The above results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 04.09.2017.
- 5) The Company has adopted Indian Accounting Standards ("Ind AS") from April 1, 2017 and accordingly these financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable to the Company. The date of transition to Ind AS is April 1, 2016. The impact of transition has been accounted for in the opening results and the comparative period results have been restated accordingly.
- 6) The Ind AS compliant financial results, pertaining to period June 30, 2016 have not been subject to limited review or audit. However, the management has exercised necessary due diligence to ensure that such financial results provide true and fair view of its affairs.
- 7) The statement does not include Ind AS compliant results for the preceding quarter and previous year ended March 31, 2017 as the same is not mandatory as per SEBI's Circular dated July 5, 2016.
- 8) Reconciliation of Net Profit as previously reported on account of transition from the previous GAAP to Ind AS for the quarter ended 30th June 2016 :


(Amount in INR Lacs)

Particulars	For the Quarter ended June 30, 2016
Net Profit as per previous GAAP	549.80
Fair Valuation of Financial Instruments	0.61
Fair Valuation of Financial guarantees	0.63
Interest expenses accounted using effective interest rate	(30.74)
Depreciation on property, plant and equipment measured at fair value as deemed cost	(4.25)
Actuarial (gain)/ Loss on employee defined benefit fund recognised in Other Comprehensive Income	(0.17)
Effect of deferred tax on adjustments	0.06
Net Profit for the period as per Ind AS	515.94
Other Comprehensive Income	0.11
Total Comprehensive Income under Ind AS	516.05



For M. T. Ankleshwaria & Co.
Chartered Accountants

Madhu T. Ankleshwaria
Proprietor



By Order of the Board
For THEMIS MEDICARE LTD

Dr. SACHIN PATEL
(Managing Director & CEO)

Place : Mumbai

Date : 04 / 09 / 2017